您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

中国医药研发对照标品提供商
Non-clinical Research-used
Medicine Sample Provider

当前本网站药物产品种数共 8420 处方药 8047 非处方药 267 保健品/医疗用具 106

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:


QQ客服1:1793093587
QQ客服2:1586083059
QQ客服3:2786706041
QQ客服6:2992753224
QQ客服7:2394834588

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 西班牙药房
产地国家: 西班牙
所属类别: 神经系统药物->中枢兴奋药
处方药:保健药品
包装规格: 18毫克/片 30片/盒
计价单位:
   
生产厂家中文参考译名:
扬森
生产厂家英文名:
JANSSEN-CILAG
该药品相关信息网址1:
http://www.igenericdrugs.com/gd.cgi?notran=1&s=CONCERTA&search=SEARCH
原产地英文商品名:
CONCERTA Prolonged-Release 18mg 30 Tablets
原产地英文药品名:
Methylphenidate Hydrochloride
中文参考商品译名:
专司达缓释片 18毫克/片 30片/盒
中文参考药品译名:
盐酸哌甲酯
原产地国家批准上市年份:
0000/00/00
英文适应病症1:
Attention deficit disorder (ADD)
英文适应病症2:
Attention deficit hyperactivity disorder (ADHD)
英文适应病症3:
Narcolepsy
临床试验期:
完成
中文适应病症参考翻译1:
注意力缺陷障碍
中文适应病症参考翻译2:
注意缺陷多动障碍
中文适应病症参考翻译3:
嗜睡症
药品信息:

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(201411504405922.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------
部分中文专司达处方资料(仅供参考)

CONCERTA (专司达)简介: < / P >

这种药物的设计很特别,它是利用一种称为OROS的制造方法,激光打孔技术,在胶囊药物(该胶囊是由人类在体外排泄的粪便不被吸收),创下了孔在前方,使得药物可以缓慢释放。胶囊被分为三个部分,最下面的部分是一个推进机构,中间是高浓度的药物,该药物的浓度是低的前面,然后包裹药物的外层上。因此,考虑使用Concerta专思达后,外层是首次发布的药品,行动可以开始下一阶段的推进机制,将吸收的水分在胃里15分钟内慢慢膨胀胶囊药物释放,启动前的低剂量剂量,中,随剂量的前部慢慢混合,药物浓度在剂量的释放开始时,最终的高剂量胶囊后推半路上,以维持所需的药物PM剂量。这种药剂旨在让孩子每天持续治疗。 < / P >

专司达在早晨服用一次,作用可维持12小时。儿童用药的数量中午取出,使他们的隐私和安全性提高,但也容易让孩子在晚上完成家庭作业,并改善亲子生活。在美国小儿科学会的建议,专司达是治疗的第一线,是美国目前使用药物的人的最大数目

Concerta - Concerta is a central nervous system stimulant used most commonly in the treatment of attention-deficit disorders in children and for narcolepsy. Its mechanisms appear to be similar to those of dextroamphetamine.

Indication: For use as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.

Concerta is a central nervous system stimulant. It affects chemicals in the brain and nerves that contribute to hyperactivity and impulse control.

Concerta is used to treat attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), and narcolepsy.

Concerta may also be used for other purposes not listed in this medication guide.

Treatment of attention-deficit hyperactivity disorder (ADHD). The efficacy of Concerta in the treatment of ADHD was established in controlled trials of children and adolescents aged 6-17 and adults aged 18-65 who met DSM-IV criteria for ADHD. Concerta should be used as a part of a comprehensive treatment program where remedial measures alone prove insufficient. A comprehensive treatment program for the treatment of ADHD may include other measures (psychological, educational, social) for patients with this disorder. Diagnosis must be made according to DSM-IV criteria or the guidelines in ICD-10 and should be based on a complete history and evaluation of the patient. Concerta is not indicated in all patients with ADHD and the decision to use the drug must be based on a very thorough assessment of the severity of the patient's symptoms. Stimulants are not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders including psychosis. Appropriate educational placement is essential and psychosocial intervention is often helpful. Specific etiology of the syndrome is unknown and there is no single diagnostic test. Adequate diagnosis requires the use of medical and special psychological, educational, and social resources. Learning may or may not be impaired.

Concerta is used to treat attention deficit hyperactive disorder (ADHD). People with ADHD may have problems concentrating on a given task and may have short attention spans. They may also be impulsive, restless and hyperactive. Concerta is meant to be taken as part of a complete ADHD care programme which includes psychological, educational and social measures. Concerta is also used to treat excessive daytime sleepiness (narcolepsy).

Attention Deficit Hyperactivity Disorder (ADHD) Concerta ®

Treatment of attention deficit hyperactivity disorder (ADHD). The efficacy of Concerta in the treatment of ADHD was established in 3 controlled trials of children 6-12 years who met DSM-IV criteria for ADHD. Concerta should be used as a part of a comprehensive treatment program where remedial measures alone prove insufficient. A comprehensive treatment program for the treatment of ADHD may include other measures (psychological, educational, social) for patients with this disorder. Diagnosis must be made according to DSM-IV criteria or the guidelines in ICD-10 and should be based on a complete history and evaluation of the patient. Concerta treatment is not indicated in all patients with ADHD and the decision to use the drug must be based on a very thorough assessment of the severity of the patient's symptoms. Stimulants are not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. Appropriate educational placement is essential, and psychosocial intervention is often helpful. Specific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use of medical and special psychological, educational and social resources. Learning may or may not be impaired.

Treatment of Attention Deficit Hyperactivity Disorder (ADHD). The efficacy of Concerta in the treatment of ADHD was established in 3 controlled trials of children aged 6-12 years who met DSM-IV criteria for ADHD.

Treatment of attention deficit hyperactivity disorder (ADHD). The efficacy of Concerta in the treatment of ADHD was established in controlled trials of children and adolescents 6-17 years and adults 18-65 years who met DSM-IV criteria for ADHD. Concerta should be used as a part of a comprehensive treatment program where remedial measures alone prove insufficient. A comprehensive treatment program for the treatment of ADHD may include other measures (psychological, educational, social) for patients with this disorder. Diagnosis must be made according to DSM-IV criteria or the guidelines in ICD-10 and should be based on a complete history and evaluation of the patient. Concerta treatment is not indicated in all patients with ADHD and the decision to use the drug must be based on a very thorough assessment of the severity of the patient's symptoms. Stimulants are not intended for use in the patient who exhibit symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. Appropriate educational placement is essential and psychosocial intervention is often helpful. Specific etiology of this syndrome is unknown and there is no single diagnostic test. Adequate diagnosis requires the use of medical and special psychological, educational and social resources. Learning may or may not be impaired.

Concerta is a central nervous system stimulant. It affects chemicals in the brain and nerves that contribute to hyperactivity and impulse control. Exactly how it works is not known. Methylphenidate is used to treat attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD). It is also used to treat uncontrollable periods of daytime sleep (narcolepsy).

更新日期: 2014-05-26
附件:
201411504405922.pdf    

 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:info.shijiebiaopin.com@gmail.com, info@shijiebiaopin.com